NZ598588A - Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors - Google Patents
Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitorsInfo
- Publication number
- NZ598588A NZ598588A NZ598588A NZ59858810A NZ598588A NZ 598588 A NZ598588 A NZ 598588A NZ 598588 A NZ598588 A NZ 598588A NZ 59858810 A NZ59858810 A NZ 59858810A NZ 598588 A NZ598588 A NZ 598588A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- taxane
- albumin
- medicament
- combination therapy
- Prior art date
Links
- 229940123237 Taxane Drugs 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title abstract 3
- 241000289669 Erinaceus europaeus Species 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 102000009027 Albumins Human genes 0.000 abstract 2
- 108010088751 Albumins Proteins 0.000 abstract 2
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 206010017758 gastric cancer Diseases 0.000 abstract 2
- 208000014018 liver neoplasm Diseases 0.000 abstract 2
- 201000011549 stomach cancer Diseases 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 206010004146 Basal cell carcinoma Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000000172 Medulloblastoma Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23681309P | 2009-08-25 | 2009-08-25 | |
| PCT/US2010/046684 WO2011025838A1 (en) | 2009-08-25 | 2010-08-25 | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ598588A true NZ598588A (en) | 2014-05-30 |
Family
ID=43628371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ598588A NZ598588A (en) | 2009-08-25 | 2010-08-25 | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20130045240A1 (enExample) |
| EP (2) | EP3103452A1 (enExample) |
| JP (1) | JP2013503174A (enExample) |
| KR (1) | KR20120053052A (enExample) |
| CN (1) | CN102573832B (enExample) |
| AU (1) | AU2010286670B2 (enExample) |
| BR (1) | BR112012004149A2 (enExample) |
| CA (1) | CA2772301A1 (enExample) |
| CR (1) | CR20120115A (enExample) |
| DK (1) | DK2470173T3 (enExample) |
| ES (1) | ES2577024T3 (enExample) |
| HR (1) | HRP20160551T8 (enExample) |
| HU (1) | HUE029094T2 (enExample) |
| IL (1) | IL218316A (enExample) |
| IN (1) | IN2012DN02018A (enExample) |
| MX (1) | MX340670B (enExample) |
| MY (1) | MY162514A (enExample) |
| NI (1) | NI201200030A (enExample) |
| NZ (1) | NZ598588A (enExample) |
| PL (1) | PL2470173T3 (enExample) |
| PT (1) | PT2470173E (enExample) |
| RU (1) | RU2561055C2 (enExample) |
| SG (2) | SG178873A1 (enExample) |
| UA (1) | UA110196C2 (enExample) |
| WO (1) | WO2011025838A1 (enExample) |
| ZA (1) | ZA201201531B (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| SI3248600T1 (sl) | 2005-02-18 | 2020-09-30 | Abraxis Bioscience, Llc | Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| PL1931321T3 (pl) | 2005-08-31 | 2019-08-30 | Abraxis Bioscience, Llc | Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe |
| EP3470071A1 (en) * | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| LT2481402T (lt) * | 2007-03-07 | 2018-10-25 | Abraxis Bioscience, Llc | Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą |
| WO2008150532A1 (en) * | 2007-06-01 | 2008-12-11 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| EP2942346B1 (en) | 2009-02-17 | 2020-05-06 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as cxcr2 modulators |
| MX378130B (es) * | 2009-04-15 | 2025-03-10 | Abraxis Bioscience Llc | Métodos y composiciones de nanopartículas sin priones. |
| PT2552438T (pt) | 2010-03-26 | 2016-07-07 | Abraxis Bioscience Llc | Métodos de tratamento de carcinoma hepatocelular |
| AU2011232862B2 (en) | 2010-03-29 | 2016-03-03 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| EP3141245A1 (en) | 2010-03-29 | 2017-03-15 | Abraxis BioScience, LLC | Methods of treating cancer |
| US20130109672A1 (en) | 2010-04-29 | 2013-05-02 | The United States Of America,As Represented By The Secretary, Department Of Health And Human Service | Activators of human pyruvate kinase |
| ES2639038T3 (es) * | 2010-06-02 | 2017-10-25 | Abraxis Bioscience, Llc | Métodos para el tratamiento de cáncer de vejiga |
| BR112012030909A2 (pt) * | 2010-06-04 | 2020-08-18 | Abraxis Bioscience, Llc | métodos de tratamento de câncer pancreático |
| AU2011264590B2 (en) * | 2010-06-07 | 2016-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| WO2012027289A1 (en) * | 2010-08-23 | 2012-03-01 | Syntrix Biosystems Inc. | Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators |
| AU2012249371B2 (en) | 2011-04-28 | 2017-06-08 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| US8945627B2 (en) | 2011-05-05 | 2015-02-03 | Wisconsin Alumni Research Foundation | Micelles for the solubilization of gossypol |
| RU2705998C2 (ru) | 2011-12-14 | 2019-11-13 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Применение полимерных эксципиентов для лиофилизации или заморозки частиц |
| WO2013112859A1 (en) | 2012-01-27 | 2013-08-01 | New York University | Method for enhancing remyelination using gli1 inhibitors |
| CN103570625A (zh) | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
| WO2014062511A1 (en) * | 2012-10-15 | 2014-04-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| WO2014087413A1 (en) * | 2012-12-03 | 2014-06-12 | Vishwa Vidya Peetham University Amrita | Nanoparticles comprising sorafenib |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US10744110B2 (en) * | 2013-03-12 | 2020-08-18 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| CA2903548A1 (en) | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| US9776996B2 (en) * | 2013-03-15 | 2017-10-03 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US9045477B2 (en) | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2014179678A1 (en) * | 2013-05-03 | 2014-11-06 | Angiostrass Llc | Methods of treating cancer and angioproliferative disorders |
| MX367554B (es) * | 2013-06-05 | 2019-08-27 | C&C Res Lab | Derivados heterocíclicos y sus usos. |
| US9914740B2 (en) | 2013-07-02 | 2018-03-13 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
| ES2634628T3 (es) | 2013-07-02 | 2017-09-28 | Bristol-Myers Squibb Company | Derivados tricíclicos de pirido-carboxamida como inhibidores ROCK |
| WO2015003360A2 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
| US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
| CA2922889A1 (en) | 2013-09-17 | 2015-03-26 | Genentech, Inc. | Methods of using anti-lgr5 antibodies |
| GB201416513D0 (en) | 2014-09-18 | 2014-11-05 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| CN111170998B (zh) * | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| KR20160066490A (ko) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
| SG11201706989SA (en) | 2015-02-27 | 2017-09-28 | Curtana Pharmaceuticals Inc | Inhibition of olig2 activity |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| JP2018521021A (ja) | 2015-06-11 | 2018-08-02 | バジリア・ファルマスーチカ・インターナショナル・アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ａｇ | 排出ポンプ阻害剤及びその治療的使用 |
| KR102606071B1 (ko) | 2015-06-29 | 2023-11-27 | 아브락시스 바이오사이언스, 엘엘씨 | 상피양 세포 종양을 치료하는 방법 |
| CN106421786A (zh) * | 2015-08-06 | 2017-02-22 | 复旦大学 | Hedgehog通路抑制剂和纳米药物递送系统的药物组合物及其用途 |
| JP2018052878A (ja) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | ピリジン化合物 |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| KR102837015B1 (ko) | 2018-03-20 | 2025-07-23 | 아브락시스 바이오사이언스, 엘엘씨 | mTOR 억제제 및 알부민의 나노입자의 투여를 통한 중추 신경계 장애의 치료 방법 |
| CN114126656A (zh) | 2019-05-29 | 2022-03-01 | 内卢姆公司 | 治疗癌症的方法和用途 |
| CA3158764A1 (en) | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| CN112755042A (zh) * | 2019-11-06 | 2021-05-07 | 绍兴维帆生物技术有限公司 | 一种抗肿瘤药物的联合使用治疗白血病的方法 |
| KR102526793B1 (ko) * | 2021-11-03 | 2023-04-28 | 주식회사 에스엔바이오사이언스 | 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법 |
| WO2025120550A1 (ko) * | 2023-12-08 | 2025-06-12 | 제이더블유중외제약 주식회사 | 헤테로사이클 유도체 제조에 사용되는 중간체 화합물, 이의 제조 방법 및 이를 이용한 헤테로사이클 유도체의 제조 방법 |
| TW202540116A (zh) * | 2023-12-08 | 2025-10-16 | 韓商Ｊｗ製藥公司 | 用於製備雜環衍生物之中間化合物、其製備方法及使用其製備雜環衍生物之方法 |
| CN120177781B (zh) * | 2025-05-22 | 2025-08-12 | 南京师范大学 | 生物传感器及其应用和高通量筛选花姜酮生产菌的方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US20070116761A1 (en) * | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| NZ502500A (en) * | 1997-06-27 | 2002-03-28 | Vivorx Pharmaceuticals Inc | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| IL142905A0 (en) | 1998-11-02 | 2002-04-21 | Biogen Inc | Functional antagonists of hedgehog activity |
| US6291516B1 (en) | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
| EP1119368A2 (en) | 1999-03-03 | 2001-08-01 | Biogen, Inc. | Methods of modulating lipid metabolism and storage |
| EP1183271A1 (en) | 1999-06-01 | 2002-03-06 | Biogen, Inc. | Polymer conjugates of hedgehog proteins and uses |
| US7708998B2 (en) | 2000-10-13 | 2010-05-04 | Curis, Inc. | Methods of inhibiting unwanted cell proliferation using hedgehog antagonists |
| US20050192262A1 (en) * | 2001-03-13 | 2005-09-01 | Tomas Hagstrom | Treatment of tumours |
| AU2002327390B2 (en) | 2001-07-27 | 2008-06-26 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| ITMI20020680A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| US7655674B2 (en) | 2002-04-22 | 2010-02-02 | The Johns Hopkins University | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| FR2850022B1 (fr) * | 2003-01-22 | 2006-09-08 | Centre Nat Rech Scient | Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications |
| PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| WO2006039569A1 (en) * | 2004-09-30 | 2006-04-13 | The University Of Chicago | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents |
| EP1807074B1 (en) * | 2004-11-03 | 2013-10-23 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| SI3248600T1 (sl) * | 2005-02-18 | 2020-09-30 | Abraxis Bioscience, Llc | Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija |
| EP3527202A1 (en) | 2005-08-31 | 2019-08-21 | Abraxis BioScience, LLC | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| WO2007056135A1 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Method of treating cancers with saha and pemetrexed |
| AR054215A1 (es) * | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| EP1998785A4 (en) | 2006-02-21 | 2009-06-17 | Univ Michigan | TREATMENT OF CANCER BY AN ANTAGONIST OF THE HEDGEHOG SIGNALING PATH |
| DE102006038747A1 (de) | 2006-08-17 | 2008-03-20 | Khs Ag | Dichtanordnung für eine Drehlagervorrichtung |
| JP4897518B2 (ja) | 2007-03-02 | 2012-03-14 | 株式会社ニチベイ | ブラインドの操作装置 |
| AU2008224941C1 (en) * | 2007-03-14 | 2013-06-27 | Exelixis Patent Company Llc | Inhibitors of the hedgehog pathway |
| KR101473504B1 (ko) * | 2007-03-15 | 2014-12-16 | 노파르티스 아게 | 유기 화합물 및 그의 용도 |
| CA2686736A1 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension |
| AU2008262056A1 (en) * | 2007-06-07 | 2008-12-18 | Irm Llc | Biphenylcarboxamide derivatives as hedgehog pathway modulators |
| US20090123932A1 (en) * | 2007-11-09 | 2009-05-14 | Anne-Marie Mes-Masson | Quantitative test to detect disease progression markers of epithelial ovarian cancer patients |
| CA2710377A1 (en) * | 2007-12-27 | 2009-07-09 | Infinity Pharmaceuticals, Inc. | Therapeutic cancer treatments |
| US8030454B2 (en) * | 2007-12-28 | 2011-10-04 | Genentech, Inc. | Anti-hedgehog antibodies |
-
2010
- 2010-08-25 MX MX2012002460A patent/MX340670B/es active IP Right Grant
- 2010-08-25 NZ NZ598588A patent/NZ598588A/en not_active IP Right Cessation
- 2010-08-25 IN IN2018DEN2012 patent/IN2012DN02018A/en unknown
- 2010-08-25 MY MYPI2012000838A patent/MY162514A/en unknown
- 2010-08-25 BR BR112012004149A patent/BR112012004149A2/pt not_active Application Discontinuation
- 2010-08-25 US US13/392,501 patent/US20130045240A1/en not_active Abandoned
- 2010-08-25 CN CN201080045983.0A patent/CN102573832B/zh active Active
- 2010-08-25 PT PT108125931T patent/PT2470173E/pt unknown
- 2010-08-25 AU AU2010286670A patent/AU2010286670B2/en active Active
- 2010-08-25 EP EP16167017.9A patent/EP3103452A1/en not_active Withdrawn
- 2010-08-25 SG SG2012013157A patent/SG178873A1/en unknown
- 2010-08-25 HR HRP20160551TT patent/HRP20160551T8/hr unknown
- 2010-08-25 UA UAA201203446A patent/UA110196C2/uk unknown
- 2010-08-25 ES ES10812593.1T patent/ES2577024T3/es active Active
- 2010-08-25 KR KR1020127007526A patent/KR20120053052A/ko not_active Ceased
- 2010-08-25 RU RU2012111235/15A patent/RU2561055C2/ru active
- 2010-08-25 WO PCT/US2010/046684 patent/WO2011025838A1/en not_active Ceased
- 2010-08-25 EP EP10812593.1A patent/EP2470173B1/en active Active
- 2010-08-25 JP JP2012526948A patent/JP2013503174A/ja active Pending
- 2010-08-25 SG SG10201609290PA patent/SG10201609290PA/en unknown
- 2010-08-25 DK DK10812593.1T patent/DK2470173T3/en active
- 2010-08-25 HU HUE10812593A patent/HUE029094T2/hu unknown
- 2010-08-25 PL PL10812593.1T patent/PL2470173T3/pl unknown
- 2010-08-25 CA CA2772301A patent/CA2772301A1/en not_active Abandoned
-
2012
- 2012-02-24 NI NI201200030A patent/NI201200030A/es unknown
- 2012-02-26 IL IL218316A patent/IL218316A/en active IP Right Grant
- 2012-02-29 ZA ZA2012/01531A patent/ZA201201531B/en unknown
- 2012-03-12 CR CR20120115A patent/CR20120115A/es unknown
-
2013
- 2013-02-28 US US13/781,487 patent/US20140072630A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ598588A (en) | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors | |
| NZ602382A (en) | Methods of treatment of hepatocellular carcinoma | |
| PH12016502066A1 (en) | Methods of treating bladder cancer | |
| HK1216853A1 (zh) | 治療胰腺癌的方法 | |
| NZ731797A (en) | Dna-pk inhibitors | |
| IL201284A (en) | K3pi alpha pyridopyrimidinone inhibitor for use in combination with one or more therapeutic agents selected from Taxol, Rapamycin, Carboplatin and Arlutinib for cancer treatment | |
| PH12012500504A1 (en) | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer | |
| MX2010009782A (es) | Tratamientos antitumorales mejorados. | |
| MX364637B (es) | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. | |
| IL207089A (en) | Pharmaceuticals containing a combination of Dostaxel angiogenesis inhibitor and their use in the preparation of non-small cell lung cancer drugs | |
| TW201611831A (en) | Novel antitumoral use of CABAZITAXEL | |
| WO2014165412A3 (en) | Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate | |
| TN2013000333A1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| MX2010008994A (es) | Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario. | |
| GB2507700A (en) | Compositions and methods for treatment of metastatic cancer | |
| GEP20186900B (en) | Methods of treating cancer using aurora kinase inhibitors | |
| EA200971103A1 (ru) | Иммуноцитокины для лечения рака в сочетании с химиотерапевтическими агентами | |
| NZ626271A (en) | Tetrahydrofolates in combination with egfr-inhibitors | |
| WO2009038771A3 (en) | Tolperisone and tolperisone-like drugs for the treatment of k-ras associated cancers | |
| MX2010009697A (es) | Tratamientos anticancerigenos mejorados. | |
| EP2836217A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS | |
| MX2011006532A (es) | Compuestos anticancerigenos. | |
| WO2008067560A3 (en) | Compositions and methods of sphingosine kinase inhibitors for use thereof in cancer therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: ABRAXIS BIOSCIENCE, LLC, US Free format text: OLD OWNER(S): ABRAXIS BIOSCIENCE, LLC; CHUNLIN TAO; PATRICK SOONSHIONG |
|
| S883 | Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant) |
Free format text: CORRECTION TO APPLICANT (71) |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 AUG 2017 BY COMPUTER PACKAGES INC Effective date: 20141031 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 AUG 2018 BY COMPUTER PACKAGES INC Effective date: 20170801 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 AUG 2019 BY COMPUTER PACKAGES INC Effective date: 20180731 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 AUG 2020 BY COMPUTER PACKAGES INC Effective date: 20190731 |
|
| LAPS | Patent lapsed |